Vinnova

Vinnova is Sweden’s Innovation Agency. Vinnova’s mission is to strengthen Sweden’s innovative capacity and contribute to sustainable growth. Vinnova’s work on several levels including identification of needs, connecting actors and funding needs driven research and innovation.

Role of institution in the project

Contributing to long term sustainability and connections to national authorities and initiatives.

Malin Eklund

Malin Eklund has a PhD in biotechnology from the Royal Institute of Technology, KTH in Stockholm Sweden. After more than 10 years as a senior researcher and project manager within the pharmaceutical industry she joined the Swedish Re-search Council in 2014. During 2015-2017 she was working for the research council from Brussels focusing on a wide range of topics including health data and per-sonalised medicine. In the beginning of 2021 Dr. Eklund started working for Vinnova. She is part of the team for Precision Health with a continued focus on improved and secure utilization of health data as well as strengthening international collaboration. She is representing Vinnova in the International Consortium of Personalised Medicine and member state representative in the 1+Million Genomes initiative signatory group.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.